Bausch Health (TSX:BHC) Beneish M-Score: -2.65 (As of Jun. 25, 2026)


TSX:BHC Bausch Health Companies Inc TSX:BHC
64 GF Score
Price C$7.10
GF Value C$11.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Bausch Health Beneish M-Score?

Bausch Health TSX:BHC +4.11% 64 Beneish M-Score is -2.65 as of Jun. 25, 2026. GuruFocus rates TSX:BHC with a GF Score™ of 64/100 and a GF Value™ of C$11.06 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Bausch Health ranks better than 63.67% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.65 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bausch Health's Beneish M-Score or its related term are showing as below:

TSX:BHC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.99   Med: -2.64   Max: -2.21
Current: -2.65

During the past 13 years, the highest Beneish M-Score of Bausch Health was -2.21. The lowest was -2.99. And the median was -2.64.


Bausch Health Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bausch Health's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health Beneish M-Score Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.56 -2.30 -2.57 -2.60 -2.58

Bausch Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.65 -2.67 -2.53 -2.58 -2.65

TSX:BHC vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch Health Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bausch Health's Beneish M-Score falls into.


TSX:BHC
64GF Score
Bausch Health Companies Inc TSX:BHC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch Health Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bausch Health for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9475+0.528 * 0.9962+0.404 * 0.9419+0.892 * 1.0666+0.115 * 1.0778
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9406+4.679 * -0.035712-0.327 * 1.0337
=-2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was C$3,006 Mil.
Revenue was 3462.928 + 3857.082 + 3708.895 + 3458.004 = C$14,487 Mil.
Gross Profit was 2450.392 + 2756.241 + 2671.345 + 2413.769 = C$10,292 Mil.
Total Current Assets was C$8,202 Mil.
Total Assets was C$33,611 Mil.
Property, Plant and Equipment(Net PPE) was C$2,874 Mil.
Depreciation, Depletion and Amortization(DDA) was C$1,648 Mil.
Selling, General, & Admin. Expense(SGA) was C$4,720 Mil.
Total Current Liabilities was C$6,215 Mil.
Long-Term Debt & Capital Lease Obligation was C$27,296 Mil.
Net Income was -1952.356 + -154.504 + 247.629 + 202.286 = C$-1,657 Mil.
Non Operating Income was -2034.676 + -531.108 + -29.051 + 184.518 = C$-2,410 Mil.
Cash Flow from Operations was 315.56 + 682.853 + 560.277 + 395.005 = C$1,954 Mil.
Total Receivables was C$2,975 Mil.
Revenue was 3243.02 + 3645.807 + 3400.046 + 3293.311 = C$13,582 Mil.
Gross Profit was 2236.665 + 2610.05 + 2457.244 + 2307.922 = C$9,612 Mil.
Total Current Assets was C$8,229 Mil.
Total Assets was C$37,930 Mil.
Property, Plant and Equipment(Net PPE) was C$2,702 Mil.
Depreciation, Depletion and Amortization(DDA) was C$1,747 Mil.
Selling, General, & Admin. Expense(SGA) was C$4,705 Mil.
Total Current Liabilities was C$6,110 Mil.
Long-Term Debt & Capital Lease Obligation was C$30,475 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3006.052 / 14486.909) / (2974.563 / 13582.184)
=0.207501 / 0.219005
=0.9475

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9611.881 / 13582.184) / (10291.747 / 14486.909)
=0.707683 / 0.710417
=0.9962

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8201.816 + 2874.34) / 33611.256) / (1 - (8228.859 + 2701.799) / 37929.988)
=0.670463 / 0.71182
=0.9419

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=14486.909 / 13582.184
=1.0666

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1747.241 / (1747.241 + 2701.799)) / (1647.723 / (1647.723 + 2874.34))
=0.392723 / 0.364374
=1.0778

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4719.733 / 14486.909) / (4704.585 / 13582.184)
=0.325793 / 0.346379
=0.9406

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((27295.94 + 6215.16) / 33611.256) / ((30474.917 + 6109.914) / 37929.988)
=0.99702 / 0.964536
=1.0337

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1656.945 - -2410.317 - 1953.695) / 33611.256
=-0.035712

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bausch Health has a M-score of -2.65 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.65 mean?
Bausch Health (TSX:BHC) has a Beneish M-Score of -2.65 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bausch Health and its competitors. According to the industry distribution chart, Bausch Health ranks #331 out of 911 companies in the Drug Manufacturers industry, placing it in the top 36.3%.
Is Bausch Health's Beneish M-Score too high?
Bausch Health's current Beneish M-Score is -2.65. Based on the distribution chart, Bausch Health ranks #331 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bausch Health has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #331 out of 911 companies for Beneish M-Score. This puts Bausch Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bausch Health and its competitors. Bausch Health's current Beneish M-Score is -2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (TSX:BHC) is currently considered Possible Value Trap. The stock's GF Value™ is C$11.06, compared to a current price of C$7.10 — trading 35.8% below its estimated fair value. The current Beneish M-Score is -2.65. Bausch Health's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bausch Health (TSX:BHC), the current Beneish M-Score is -2.65 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (TSX:BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of C$7.10 is trading 35.8% below its estimated GF Value™ of C$11.06. GuruFocus considers Bausch Health to be Possible Value Trap.

Key valuation signals for TSX:BHC:

  • Beneish M-Score: -2.65
  • GF Value™: C$11.06 vs. price of C$7.10 (35.8% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TSX:BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
64GF Score

Get the complete analysis for TSX:BHC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$7.10
Price
C$11.06
GF Value